BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26424413)

  • 21. Simplify p53: just an activator.
    Engeland K
    Oncotarget; 2015 Jan; 6(1):3-4. PubMed ID: 25575818
    [No Abstract]   [Full Text] [Related]  

  • 22. Cell death decision by p53 via control of the mitochondrial membrane.
    Dashzeveg N; Yoshida K
    Cancer Lett; 2015 Oct; 367(2):108-12. PubMed ID: 26231733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53: more research and more questions.
    Braithwaite AW; Prives CL
    Cell Death Differ; 2006 Jun; 13(6):877-80. PubMed ID: 16708075
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic silencing of 14-3-3sigma in cancer.
    Lodygin D; Hermeking H
    Semin Cancer Biol; 2006 Jun; 16(3):214-24. PubMed ID: 16698281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis.
    Solomon H; Brosh R; Buganim Y; Rotter V
    Discov Med; 2010 May; 9(48):448-54. PubMed ID: 20515613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of cell cycle components by epigenetic and genetic events.
    Macaluso M; Montanari M; Cinti C; Giordano A
    Semin Oncol; 2005 Oct; 32(5):452-7. PubMed ID: 16210085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disarming mutant p53 oncogenic function.
    Girardini JE; Marotta C; Del Sal G
    Pharmacol Res; 2014 Jan; 79():75-87. PubMed ID: 24246451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
    Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
    Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RelB inhibits cell proliferation and tumor growth through p53 transcriptional activation.
    Jacque E; Billot K; Authier H; Bordereaux D; Baud V
    Oncogene; 2013 May; 32(21):2661-9. PubMed ID: 22777360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. α-Catulin knockdown induces senescence in cancer cells.
    Fan LC; Chiang WF; Liang CH; Tsai YT; Wong TY; Chen KC; Hong TM; Chen YL
    Oncogene; 2011 Jun; 30(23):2610-21. PubMed ID: 21278790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The p53 gene and protein in 2005: new results, promising opportunities].
    Szoke D; Sipos F; Spisák S; Molnár B; Tulassay Z
    Orv Hetil; 2005 Jul; 146(30):1587-94. PubMed ID: 16136736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Crusade against Mutant p53: Does the COMPASS Point to the Holy Grail?
    Abraham CG; Espinosa JM
    Cancer Cell; 2015 Oct; 28(4):407-408. PubMed ID: 26461087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Putting p53 in Context.
    Kastenhuber ER; Lowe SW
    Cell; 2017 Sep; 170(6):1062-1078. PubMed ID: 28886379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer: Mutant p53 and chromatin regulation.
    Prives C; Lowe SW
    Nature; 2015 Sep; 525(7568):199-200. PubMed ID: 26331537
    [No Abstract]   [Full Text] [Related]  

  • 36. CSL-p53: From senescence to CAF activation.
    Procopio MG; Laszlo C; Dotto GP
    Cell Cycle; 2016; 15(4):485-6. PubMed ID: 26735629
    [No Abstract]   [Full Text] [Related]  

  • 37. Hitting cancers' weak spots: vulnerabilities imposed by p53 mutation.
    Gurpinar E; Vousden KH
    Trends Cell Biol; 2015 Aug; 25(8):486-95. PubMed ID: 25960041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer genomics identifies disrupted epigenetic genes.
    Simó-Riudalbas L; Esteller M
    Hum Genet; 2014 Jun; 133(6):713-25. PubMed ID: 24104525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment.
    Sun XX; Yu Q
    Acta Pharmacol Sin; 2015 Oct; 36(10):1219-27. PubMed ID: 26388155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amyloid Evolvability and Cancer.
    Takamatsu Y; Ho G; Hashimoto M
    Trends Cancer; 2020 Aug; 6(8):624-627. PubMed ID: 32386876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.